Gilead (GILD): Revisiting Valuation After HIV Wins and New U.S. Drug Pricing Agreement

Gilead Sciences (GILD) just strung together a trio of catalysts that the market could not ignore, including fresh HIV wins and a high profile U.S. drug pricing deal that reframes its long term growth story.

See our latest analysis for Gilead Sciences.

The latest HIV data and U.S. pricing accord appear to be feeding into a stronger narrative for Gilead, with the stock’s share price up meaningfully year to date and longer term total shareholder returns reinforcing that momentum.

If breakthroughs in HIV and pricing reform are on your radar, it is also worth exploring other pharmaceutical names via pharma stocks with solid dividends for fresh ideas beyond Gilead.

With shares up more than 35% year to date and trading only a modest discount to Wall Street targets, should investors treat Gilead as a still underappreciated cash flow machine, or assume the market is already pricing in its next leg of growth?

Most Popular Narrative Narrative: 4.9% Undervalued

Compared with Gilead Sciences last close of $124.29, the most followed narrative points to a slightly higher fair value anchored in resilient HIV earnings and expanding margins.

The launch and scaling of innovative products (Yeztugo, Trodelvy first line, Livdelzi) position Gilead to deliver a more favorable product mix and premium pricing, driving higher gross margins and improving long term earnings trajectory as portfolio diversification reduces overexposure to legacy products.

Read the complete narrative.

Want to see how steady topline growth, rising margins, and a richer product mix combine into this valuation call? The narrative hinges on bold earnings and multiple assumptions you will want to stress test yourself.

Result: Fair Value of $130.63 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this upbeat case still hinges on Gilead navigating policy driven pricing pressure and successfully executing its HIV and oncology diversification plans.

Find out about the key risks to this Gilead Sciences narrative.

Build Your Own Gilead Sciences Narrative

If you are not convinced by this view or prefer to dig into the numbers yourself, you can build a custom narrative in minutes: Do it your way.

A great starting point for your Gilead Sciences research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

Do not stop at Gilead when the market is full of potential. Use the Simply Wall Street Screener to explore additional opportunities.

• Scan these 3627 penny stocks with strong financials to find companies with low share prices and strong financials.
• Use these 13 dividend stocks with yields > 3% to identify income-focused opportunities with attractive yields from established businesses.
• Explore these 913 undervalued stocks based on cash flows to look for companies trading below their estimated cash flow value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com